her left ear is itching again; experiencing discoloration/patchy areas on her skin; pain; verysick; she doesn't have full blown shingles now/bumps from the shingles; lesions on the right side and left side/in her left ear, jaw, chin, tongue, mouth, down to her left arm/she was left with what looks like craters on her face; shortness of breath; This non-serious case was reported by a nurse via call center representative and described the occurrence of shingles in a 60-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included dupilumab (Dupixent) for nasal polyp.   The patient's past medical history included shingles (on the left side of her face and in her left ear) and nerve pain. Previously administered products included Valtrex (received 2 rounds of Valtrex and Neurontin for the nerve pain which was all gone) and Neurontin. Concurrent medical conditions included nasal polyp.   On 11-AUG-2023, the patient received the 1st dose of Shingrix. On 15-AUG-2023, the patient started Dupixent. In AUG-2023, an unknown time after receiving Shingrix, the patient experienced shortness of breath (Verbatim: shortness of breath). On 19-AUG-2023, the patient experienced shingles (Verbatim: she doesn't have full blown shingles now/bumps from the shingles) and skin lesion (Verbatim: lesions on the right side and left side/in her left ear, jaw, chin, tongue, mouth, down to her left arm/she was left with what looks like craters on her face). On an unknown date, the patient experienced ear pruritus (Verbatim: her left ear is itching again), skin discoloration (Verbatim: experiencing discoloration/patchy areas on her skin), pain (Verbatim: pain) and sickness (Verbatim: verysick).  The action taken with Dupixent was unknown. The outcome of the shingles, skin discoloration, pain and sickness were not reported and the outcome of the skin lesion was unknown and the outcome of the ear pruritus and shortness of breath were not resolved.   It was unknown if the reporter considered the shingles, skin lesion, ear pruritus, shortness of breath, skin discoloration, pain and sickness to be related to Shingrix.     It was unknown if the company considered the shingles, skin lesion, ear pruritus, shortness of breath, skin discoloration, pain and sickness to be related to Shingrix.   Additional Information: GSK Receipt Date: 11-OCT-2023 and 12-OCT-2023 The patient received the 1st dose of Shingrix on and took Dupixent. The reporter stated that she started experiencing lesions on the right side of her chin. The patient She described the lesions on the right side as what the healed shingles lesions on the left side look like now, as the lesions on the right side never did open and blister up. The patient did not know if the Dupixent had something to do with the lesion formation as she stated back when she first started taking it, she noticed patchy areas on her skin. The patient spoke to others who have taken Dupixent and they have experienced the same thing and she has not taken the Dupixent due to this. The patient stated that last week she noticed the same same lesions on the right side of her nose and her left ear is itching again, which was what she experienced when she had shingles back in July. On 19-AUG-2023, 8 days after receiving Shingrix, the patient experienced shingles and skin lesion. On 19-AUG-2023, 4 days after receiving Dupixent, the patient experienced shingles and skin lesion. The patient has not been diagnosed with shingles this time but was questioning if she should still take the Dupixent or the 2nd dose of Shingrix. It was unknown if the reporter considered the shingles, skin lesion, ear pruritus, shortness of breath, skin discoloration, pain and sickness to be related to Dupixent. The reporter consented to follow up.